Corpus ID: 4024865

Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gatric pentadecapeptide BPC 157 in rats.

@article{Vitai2017NonsteroidalAD,
  title={Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gatric pentadecapeptide BPC 157 in rats.},
  author={Sanja Vitai{\'c} and Mirjana Stupni{\vs}ek and Domagoj Drmic and Lara Bauk and Antonio Kokot and Robert Klicek and Aleksandar Vcev and Kre{\vs}imir Lueti{\'c} and Sven Seiwerth and Predrag Sikiric},
  journal={Journal of physiology and pharmacology : an official journal of the Polish Physiological Society},
  year={2017},
  volume={68 2},
  pages={
          265-272
        }
}
  • S. Vitaić, M. Stupnišek, +7 authors P. Sikiric
  • Published 2017
  • Medicine, Chemistry
  • Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
The sphincters failure is a part of NSAIDs-toxicity that can be accordingly counteracted. We used a safe stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419), LD1 not achieved, since successful in inflammatory bowel disease trials, and counteracts esophagitis, sphincters failure, gastrointestinal ulcer and skin ulcer, external and internal fistulas in rats, and particularly counteracts all NSAIDs-lesions. We assessed lower esophageal sphincter and pyloric sphincter pressure (cmH2O… Expand
8 Citations
Therapy of the rat hemorrhagic cystitis induced by cyclophosphamide. Stable gastric pentadecapeptide BPC 157, L-arginine, L-NAME.
TLDR
The cyclophosphamide-induced hemorrhagic cystitis lesions are NO-related based on the administration of L-NAME as well as administration ofL-arginine, and their mutual interaction, and counteraction by BPC 157 application and reveal new therapeutic possibilities. Expand
Fistulas healing. Stable gastric pentadecapeptide BPC 157 therapy.
TLDR
Taking fistulas as a pathological connection, this rescue is verified with the beneficial effects in rats with the various gastrointestinal anastomoses, esophagogastric, jejunoilesal, colo-colonic, ileoileal, Esophagojejunal, esphagoduodenal, and gastrojeJunal. Expand
Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the Future
We reviewed again the significance of the stable gastric pentadecapeptide BPC 157 as a likely mediator of Robert’s stomach cytoprotection/adaptive cytoprotection and organoprotection and as novelExpand
In relation to NO-System, Stable Pentadecapeptide BPC 157 Counteracts Lidocaine-Induced Adverse Effects in Rats and Depolarisation In Vitro
TLDR
BPC 157 has antidote activity in its own right against lidocaine and local anesthetics and counteracted the lidocane-induced depolarisation of HEK293 cells. Expand
Pentadecapeptide BPC 157 shortens duration of tetracaine- and oxybuprocaine-induced corneal anesthesia in rats
TLDR
The relationship of 0.5% tetracaine- and 0.4% oxybuprocaine-induced corneal anesthesia in rats, and pentadecapeptide BPC 157 along with nitric oxide synthase (NOS) inhibitor N(gamma)-nitro-L-arginine methyl ester (L-NAME) and/or NOS substrate L-arg inine is focused on. Expand
Generation of Spontaneous Tone by Gastrointestinal Sphincters.
TLDR
Various mechanisms that may contribute to tone generation in sphincters are explored including summation of asynchronous phasic activity, partial tetanus, window current, and myofilament sensitization. Expand
Physiological and pharmacological effects of glucocorticoids on the gastrointestinal tract.
TLDR
The results of experimental studies on re-evaluation of the traditional notion that stressproduced glucocorticoids are ulcerogenic led to opposite conclusion suggested that these hormones play an important role in maintenance of the gastric mucosal integrity. Expand
Nove spoznaje o stabilnom želučanom pentadekapeptidu BPC 157
Stabilni želucani pentadekapeptid BPC 157 je novi peptid protiv želucanih vrijedova, koji se koristi u ispitivanjima za lijecenje ulceroznog koli

References

SHOWING 1-10 OF 63 REFERENCES
An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157.
TLDR
The anti-ulcer gastric pentadecapeptide BPC 157, which was found to be stable in gastric juice, and is being evaluated in inflammatory bowel disease trials, is an anti-esophagitis therapy that recovers failed sphincters. Expand
Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157.
TLDR
Gastric pentadecapeptide BPC 157 (PL 14736) is given intraperitoneally and in the normal rats it increases lower esophageal sphincter pressure, but decreases the pyloric spH2O pressure, while in normal rats this treatment does not have an effect in either rats with esophagitis or in normal Rats. Expand
BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure.
TLDR
It is concluded that BPC 157 could cure esophagitis/sphincter/acute pancreatitis healing failure and anti-ulcer pentadecapeptide BPC157 affecting esophageal and pyloric sphincters failure and acute pancreatitis. Expand
Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats
TLDR
Pentadecapeptide BPC 157, applied parenterally or per-orally, appears to ameliorate the SUI in rat models, improving the otherwise detrimental course of healing after VD and TU, which may be analogous to human injury. Expand
Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.
TLDR
In rat esophagitis and failed function of both lower esophageal sphincter (LES) and pyloricSphincters (PS), BPC 157 increased pressure in both spHincters till normal and reduced esophAGitis, and may improve gastrointestinal tract therapy. Expand
Therapy for Unhealed Gastrocutaneous Fistulas in Rats as a Model for Analogous Healing of Persistent Skin Wounds and Persistent Gastric Ulcers: Stable Gastric Pentadecapeptide BPC 157, Atropine, Ranitidine, and Omeprazole
TLDR
It is concluded that BPC 157 may resolve analogous nonhealing of wounds and persistent gastric ulcers better than standard agents. Expand
Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME
TLDR
Innate NO-system disability for esophagogastric anastomoses, including L-NAME-worsening, suggests that these effects could be corrected by L-arginine and almost completely eliminated by BPC 157 therapy. Expand
Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157.
TLDR
Beneficial and counteracting effects of BPC 157 were obtained using the equipotent dosage in parenteral or peroral regimens, unlike the different dosage levels of aspirin, as a NSAIDs prototype, which differ by a factor of about ten. Expand
Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats
TLDR
Diclofenac combined with nitric oxide (NO) system blockade was used to resolve the increasing early risks following major massive small bowel resectioning surgery, suggesting therapy with BPC 157 and the Nitric oxide synthase (NOS substrate) L-arginine, is efficacious. Expand
Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats
TLDR
In the adjuvant arthritis studies, the lesion's development seems to be considerably reduced after single pentadecapeptide medication, and even more attenuated in rats daily treated with BPC 157, likely pointing to a special anti-inflammatory and mucosal integrity protective effect. Expand
...
1
2
3
4
5
...